MST, a Physiological Caspase Substrate, Highly Sensitizes Apoptosis Both Upstream and Downstream of Caspase Activation*

Kyung-Kwon LeeDagger , Takahiro OhyamaDagger , Nobuyuki YajimaDagger , Satoshi Tsubuki§, and Shin YoneharaDagger

From the Dagger  Institute for Virus Research, Kyoto University, Kyoto 606-8507 and § Institute of Physical and Chemical Research (RIKEN), Saitama 351-0198, Japan

Received for publication, June 13, 2000, and in revised form, March 5, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The human serine/threonine kinase, mammalian STE20-like kinase (MST), is considerably homologous to the budding yeast kinases, SPS1 and STE20, throughout their kinase domains. The cellular function and physiological activation mechanism of MST is unknown except for the proteolytic cleavage-induced activation in apoptosis. In this study, we show that MST1 and MST2 are direct substrates of caspase-3 both in vivo and in vitro. cDNA cloning of MST homologues in mouse and nematode shows that caspase-cleaved sequences are evolutionarily conserved. Human MST1 has two caspase-cleavable sites, which generate biochemically distinct catalytic fragments. Staurosporine activates MST either caspase-dependently or independently, whereas Fas ligation activates it only caspase-dependently. Immunohistochemical analysis reveals that MST is localized in the cytoplasm. During Fas-mediated apoptosis, cleaved MST translocates into the nucleus before nuclear fragmentation is initiated, suggesting it functions in the nucleus. Transiently expressed MST1 induces striking morphological changes characteristic of apoptosis in both nucleus and cytoplasm, which is independent of caspase activation. Furthermore, when stably expressed in HeLa cells, MST highly sensitizes the cells to death receptor-mediated apoptosis by accelerating caspase-3 activation. These findings suggest that MST1 and MST2 play a role in apoptosis both upstream and downstream of caspase activation.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Apoptosis or programmed cell death is a normal cell suicide mechanism that is highly conserved from nematode to human (1, 2). This regulated process plays a critical role during embryogenesis, tissue homeostasis, and remodeling and serves to remove unwanted or deleterious cells such as self-reactive lymphocytes, tumor cells, or virus-infected cells. Deregulation of apoptosis thus contributes to the pathogenesis of cancer, autoimmune disease, and sustained viral infection, whereas excessive apoptosis results in inappropriate cell loss and consequently degenerative disorders (3).

The Fas-mediated apoptosis has been extensively investigated as a model system of mammalian apoptotic cell death (4). Stimulation of Fas induces the translocation and recruitment of FADD together with a complex of pro-caspase-8 and FLASH to the cytoplasmic tail of Fas (5-7), forming the death-inducing signaling complex (8). Then pro-caspase-8 becomes proteolytically autoactivated by oligomerization, whereupon it stimulates other caspases, including caspase-3, caspase-6, and caspase-7, by cleaving them (9-12). These downstream caspases cleave the death substrates that are central to apoptotic events such as morphological changes and DNA fragmentation (12, 13).

MST11 and MST2 belong to a mammalian SPS1/STE20-like kinase family, which is rapidly increasing in number (14-18). However, the cellular function of MST as well as that of most other SPS1/STE20-like kinases is largely unknown. MST1 and MST2 have an N-terminal catalytic domain and C-terminal regulatory region, whereas other subfamily members such as p21-activated kinase (PAK) have a long N-terminal regulatory domain containing GTPase binding domain that confers the ability to bind to activated Cdc42 and/or Rac1 (17, 19, 20). Notably, PAK2 is proteolytically activated by caspase in Fas-mediated apoptosis and has been reported to induce morphological changes of apoptosis (21, 22). In contrast, the C-terminal regulatory region of MST does not have any known interaction motif, although this region is required for dimerization (23). Some of the MST subfamily is responsive to cellular stress; inflammatory cytokines such as tumor necrosis factor (TNF) alpha  can trigger activation of GCK, and SOK is responsive to oxidative stress (24-26). However, MST1 is only activated by non-physiological stresses such as high temperature heat shock and high concentrations of sodium arsenite or staurosporine (16).

Previously we identified a protein kinase that is strongly activated in Fas-mediated apoptosis. Biochemical purification of its activity revealed the kinase to be a catalytic fragment of MST1 (27). Fas-mediated activation of MST resulted from specific cleavage at the caspase recognition site and was inhibited by caspase inhibitor, suggesting the direct cleavage of MST by caspase. These studies suggested that MST and other SPS1/STE20 family kinases are involved in apoptosis. In the present study, we investigated the involvement of MST in apoptosis. We clearly show that both MST1 and MST2 are cleaved by caspase in vivo and in vitro. The proteolytic cleavage reveals the activation mechanism of MST and causes its cellular translocation. Most important, we show that MST can caspase-independently induce morphological changes characteristic of apoptosis and enhances the sensitivity for death receptor-mediated apoptosis in epithelial cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- GFP expression vector pCMX-SAH/Y145F, beta -galactosidase expression vector pJ7Omega -LacZ, and Caenorhabditis elegans N2 cDNA library were kindly provided by Dr. K. Umezono (Kyoto University, Japan), Dr. A. Murakami (Kyoto University, Japan), and Dr. A. Sugimoto (Tokyo University, Japan), respectively. Leptomycin was a generous gift from Dr. M. Yoshida (Tokyo University). Anti-FLAG antibody and cycloheximide were obtained from Sigma; agonistic anti-Fas antibody (CH-11) and anti-GFP antibody were from MBL Inc. (Japan); anti-caspase-3 antibody was from PharMingen; Z-VAD-fmk, DEVD-CHO, and DEVD-7-amido-4-trifluoromethylcoumarin were from Peptide Institute Inc. (Japan); human recombinant TNF was from Calbiochem.

Expression and Purification of His-tagged Proteins-- His-tagged MST was expressed as a kinase-deficient protein because kinase-active MST was poorly expressed in bacteria. Human MST cDNA with a mutation at catalytic amino acid residue (MST1K59R or MST2K56R) was subcloned in frame into His tag expression vector, pQE-30 (Qiagen). For C-terminal His-tagging, MST1K59R,D326N was subcloned into pET29a (Novagen). To obtain active His-tagged caspase-3, cDNA of human caspase-3 lacking N-terminal 28 amino acid residues was amplified by PCR using 5'-AGGGATCCTCTGGAATATCCCTGGAC-3' and 5'-TGAGCCTTTGACCATGCCCACAGA-3' as primers (underline indicates BamHI site). PCR product was double-digested with BamHI and PstI and subcloned into pQE30 vector. His-tagged proteins were expressed in BL21(DE3)lysS bacteria and purified using His-Trap affinity column as described previously (28).

Mammalian Expression Constructs-- Expression constructs of MST were prepared as an N-terminal FLAG tag. We introduced FLAG tag after the initiation codon in pME18S vector (27) and generated a FLAG-tag expression vector, pME18S-FL. The cDNA encoding full-length MST1, MST1Delta 327-487 (deleting aa 327-487), MST1Delta 1-326 (deleting aa 1-326), full-length MST2, MST2Delta 323-491 (deleting aa 323-491), and MST2Delta 1-322 (deleting aa 1-322) were amplified by PCR and inserted in frame into pME18S-FL. For GFP fusion, cDNA of MST was subcloned in frame into pCMX-SAH/Y145F. Mutagenesis of the amino acid residue was performed with Quick-Change site-directed mutagenesis kit (Stratagene) and confirmed by DNA sequencing. Human PAK2 cDNA and caspase-8 cDNA were amplified by PCR from an HPB-ALL cDNA library (29) and inserted into pME18S vector.

Preparation of Anti-MST Monoclonal Antibody-- For immunization, affinity-purified His-MST1K59R and His-MST2K56R were further loaded onto Mono-Q anionic exchange column (Amersham Pharmacia Biotech) and eluted with a linear NaCl gradient of 0.1 to 0.5 M as described (28). Purified fraction, dialyzed against 20 mM Tris·HCl (pH 7.5) containing 150 mM NaCl, was used for immunization of Balb/c mice. Establishment and cloning of hybridoma cells were performed as described previously (28). Monoclonal antibodies were purified from hybridoma culture with protein G-affinity column as described (Amersham Pharmacia Biotech) (28).

Cell Culture, Transfection, and Induction of Apoptosis-- Human thymoma-derived HPB-ALL, human acute T cell leukemia-derived Jurkat, and murine lymphoma-derived WR19L12a cells were cultured in RPMI 1640 with 10% fetal calf serum, 20 mM Hepes (pH 7.3), 50 µM beta -mercaptoethanol, 50 units/ml penicillin, and 50 µg/ml streptomycin. Murine fibroblast NIH 3T3, human adenocarcinoma-derived HeLa, and human embryonic kidney-derived 293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 100 µg/ml kanamycin. Jurkat cells were transfected by electroporation at 300 V with capacitance of 960 microfarads. NIH 3T3 or HeLa cells were seeded on glass culture slides (Nalge Nunc) or 60-mm culture plates 24 h before transfection and then transfected with LipofectAMINE (Life Technologies, Inc.) in accordance with the manufacturer's suggestion. To establish stable HeLa cell lines, pME18S-Neo vector harboring neomycin-resistant gene was co-transfected with expression vectors encoding GFP, GFP-MST1, or MST1K59R. The transfectants were grown and selected in the presence of 1 mg/ml G418. To induce apoptosis, cells were treated with anti-Fas antibody, CH-11 (0.1 µg/ml) (27, 30), TNFalpha (50 ng/ml), or staurosporine (0.5 µM). Where indicated, cells were co-treated with cycloheximide (10 µg/ml).

Preparation of Cell Lysate, Immunoprecipitation, and Immunoblot Analysis-- Cells were washed once with PBS and suspended in cold lysis buffer (40 mM Hepes (pH 7.4) with 10% glycerol, 1% Triton X-100, 0.5% Nonidet P-40, 150 mM NaCl, 50 mM NaF, 20 mM beta -glycerol phosphate, 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, and 0.1 mM vanadate) with protease inhibitor mixture (1 µg/ml aprotinin, leupeptin, and pepstatin). Cell lysates were cleared by centrifugation at 15,000 rpm for 20 min. For immunoprecipitation, cell lysate was incubated with 2 µg of anti-FLAG mAb or anti-MST mAb for 2 h at 4 °C and precipitated with protein G-Sepharose (Amersham Pharmacia Biotech). Cell lysate or immunoprecipitates were resolved by SDS-PAGE and transferred to polyvinylidene difluoride membrane (Millipore). The membrane was blocked in TBST buffer (20 mM Tris·HCl (pH 7.5) containing 150 mM NaCl and 0.1% Tween 20) with 5% skim milk at room temperature for 1 h. The membrane was incubated with anti-FLAG mAb or anti-MST mAb for 1 h, washed in TBST, and then incubated for 1 h with horseradish peroxidase-conjugated anti-mouse IgG (Amersham Pharmacia Biotech). After further washing with TBST, peroxidase activity was detected on x-ray films using an enhanced chemiluminescence detection system (DuPont).

In Vitro Cleavage Assay and Cleavage Site Mapping-- Purified His-MST1K59R or His-MST2K56R was incubated with the purified recombinant active caspase-3 at 30 °C for 30 min. The reaction was stopped by adding Laemmli's sample buffer, resolved on 10% SDS-polyacrylamide gel, and immunoblotted with anti-MST mAb. For purification of C-terminal His-tagged protein, MST1K59R,D326N was subcloned into pET29a (Novagen) and transformed into BL21(DE3)lysS bacteria. Jurkat cells were exposed to CH-11 for 4 h, and lysate was prepared in lysate buffer containing protease inhibitor mixture. Cell lysate (107 cell equivalents) was incubated with 50 µg of purified MST1K59R,D326N-His at 30 °C for 1 h, and the reaction was terminated by adding 50 µM Z-VAD-fmk. The sample was mixed with nickel-nitrilotriacetic acid-agarose (Qiagen) and incubated at 4 °C for 2 h. The resin was washed with 10 volumes of lysis buffer containing 5 mM imidazole. Laemmli's sample buffer was directly added to the resin, and cleaved proteins were separated on 15% SDS-polyacrylamide gel and transferred to polyvinylidene difluoride membrane. The membrane was immunoblotted or stained with Coomassie Brilliant Blue. The fragment was cut and analyzed by N-terminal peptide sequencing (27, 28).

Cloning of Murine and C. elegans MST Homologues-- MST homologues of mouse and C. elegans were identified by homology search against public data bases and cloned by PCR-based methods as follows. BLAST search identified overlapping EST murine cDNA clones homologous to 3' regions of human MST1 gene. To obtain a complete cDNA sequence, 5'-rapid amplification of cDNA ends PCR was carried out using a cDNA library of mouse lymphoma WR19L12a cells as template. For cloning of murine MST2, primers were designed based on the reported nucleotide sequence (GenBankTM accession number U28726), 5'-CAGGATCCGCCATGGAGCAGCCGC-3' and 5'-AACTGCAGTCAGAAATTCTGCTGCCTCC-3'. The cDNA was amplified from the WR19L12a cDNA library. The C. elegans homologue was found by a BLAST search against EST or genome data base (ACeDB). C. elegans MST was obtained from a strain N2 cDNA library by PCR using 5'-atgccaccgtctacagacag-3' and 5'-cgaagccgtcattgaagtcg-3' as primes. The cloned cDNA was compared with a genome data base (ACeDB) and matched completely with the predicted sequences by Gene Finder, a gene structure prediction program. The cDNAs of murine and C. elegans MST were subcloned pME18S-FL and pCMX-SAH/Y145F vector, respectively.

MST Kinase Assay-- Endogenous MST or various forms of FLAG-tagged MST were immunoprecipitated with 2 µg of antibody, and the same amounts of immunoprecipitates as analyzed by immunoblot were used for in-gel phosphorylation assay (27) or immune complex kinase assay. For immune complex kinase assay, immunoprecipitates were incubated with 2 µg of histone H2B in 20 µl of kinase reaction buffer (40 mM Hepes (pH 7.5) with 20 mM MgCl2, 20 mM beta -glycerol phosphate, and 0.1 mM vanadate) containing 25 µM ATP and 2.5 µCi of [gamma -32P]ATP for 20 min at 30 °C. Reactions were terminated by adding 7 µl of Laemmli's sample buffer and boiling for 5 min. A portion of the sample (15 µl) was separated on a 15% SDS-polyacrylamide gel and autoradiographed or analyzed by PhosphorImage analyzer.

beta -Galactosidase Staining-- NIH 3T3 or HeLa cells were cultured on 6-well plates and transfected with 1 µg of MST kinase expression vector and 0.2 µg of a beta -galactosidase expression vector (pLacZ). After 48 h, the cells were washed once with PBS and fixed with 2% formaldehyde and 0.2% glutaraldehyde in PBS for 5 min at 4 °C. After being further washed with PBS, the cells were overlaid with X-gal staining solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mM MgCl2, and 1 mg/ml X-gal in PBS) for 1 h at 37 °C and photographed.

Fluorescence Microscopy of Cultured Cells-- NIH 3T3 or HeLa cells on glass culture slides were washed with PBS, fixed in 3.7% formaldehyde in PBS containing 0.1% Triton X-100 for 10 min, and blocked in 2% bovine serum albumin in PBS for 10 min. Anti-FLAG mAb (1 µg/ml) was treated for 1 h and then washed in PBS. The secondary antibody, fluorescein isothiocyanate-conjugated anti-mouse antibody (Cappel), was used at a 1:500 dilution for 45 min. Cells were washed with PBS, incubated with Hoechst 33342 (0.2 µg/ml), and washed again in PBS. For fluorescence microscopy of live cells, Hoechst 33342 (0.2 µg/ml) was added in culture medium, and the cells were incubated for 30 min at 37 °C before microscopic observation. Cells were washed with PBS and observed under a 40× water immersion lens (Carl Zeiss). Samples were examined, and images were collected using Axioplan2 microscope (Carl Zeiss) connected to a CCD camera. The figures were prepared using Photoshop software (Adobe).

Fluorometric Caspase Activity Assay-- Cell lysate (100 µl) was incubated with 50 µM DEVD-7-amido-4-trifluoromethylcoumarin in reaction buffer, 10 mM Tris·HCl (pH 7.5), and 1 mM EDTA and incubated at 37 °C for 30 min. The reaction was terminated by adding an equal volume of 50 mM glycine HCl (pH 2.3), and fluorescence emission at 460 nm (excitation at 370 nm) was measured.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteolytic Cleavage and Activation of Both MST1 and MST2 by Caspase in Fas-mediated Apoptosis-- We established several hybridoma cell lines producing anti-MST mAbs, and purified mAbs were characterized by immunoblot analyses for HeLa cells transfected with FLAG-MST1 or FLAG-MST2 (Fig. 1A). Monoclonal antibody G2B equally recognized both MST1 and MST2, whereas A8C selectively recognized only MST1. When apoptosis was induced, G2B and A8C could detect a cleaved 34-kDa fragment of MST. On the contrary, J7B detected the C-terminal 21-kDa fragment of MST2. Other mAbs, DIH, F5C, and H3B, recognized N-terminal 34-kDa fragment of MST1 and MST2.2


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Characterization of anti-MST mAbs. A, FLAG-MST1 or FLAG-MST2 was expressed in HeLa cells on 6-well plates, and apoptosis was induced by 4 h of incubation with CH-11 (0.1 µg/ml) and cycloheximide (10 µg/ml). Cell lysate (20 µg) was resolved on 12% SDS-PAGE gel and immunoblotted with anti-FLAG or anti-MST mAbs as indicated. B, FLAG-MST1 and FLAG-MST2 were immunoprecipitated with anti-FLAG or the indicated anti-MST mAbs. Immunoprecipitates (IP) were resolved on SDS-PAGE gel and immunoblotted with anti-FLAG mAb. C, HPB-ALL cells (2 × 107) were preincubated without (-) or with (+) 25 µM Z-VAD-fmk for 1 h, and apoptosis was induced by incubation with CH-11 (0.1 µg/ml) for the indicated times. Cell lysates (50 µg) were analyzed by immunoblotting with anti-MST mAb, G2B.

Immunoprecipitation analysis showed that A8C and D1H selectively immunoprecipitated FLAG-MST1, whereas J7B immunoprecipitated only FLAG-MST2 (Fig. 1B). A8C could not immunoprecipitate N-terminal 34-kDa fragment although A8C recognized it in immunoblot.2 Both FLAG-MST1 and FLAG-MST2 were efficiently immunoprecipitated by G2B or H3B. With G2B and A8C anti-MST mAbs, we examined the cleavage of endogenous MST1 and MST2 during Fas-mediated apoptosis in HPB-ALL cells, which expressed both MST1 and MST2. G2B recognized a 34-kDa fragment of MST at 2 h after the stimulation of Fas (Fig. 1C). This fragment was also confirmed by immunoprecipitation (Fig. 2A). The cleavage of MST was inhibited when apoptosis was blocked by the pretreatment with Z-VAD-fmk, a broad spectrum caspase inhibitor (Fig. 1C and 2A). The molecular weight of cleaved MST coincided with that of the previously purified protein kinase from apoptotic HPB-ALL lysate, confirming our result that MST is specifically cleaved to a 34-kDa catalytic fragment in apoptosis (Fig. 2A) (27). A8C efficiently precipitated MST1 when apoptosis was not induced or Z-VAD-fmk was pretreated. However, A8C could not immunoprecipitate MST1 when apoptosis was induced (Fig. 2B). These results suggest that MST1 was completely cleaved to a fragment that could not be precipitated by A8C because A8C could immunoprecipitate only uncleaved MST1.2


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2.   MST1 and MST2 are proteolytically activated by caspase. A-D, HPB-ALL cells (5 × 107) were treated with Z-VAD-fmk and CH-11 as in the legend of Fig. 1. Aliquots of lysate were immunoprecipitated with anti-MST mAb, G2B (A and C), or A8C (B). Immunoblot analysis was performed using G2B (A) or A8C (B). As a control, purified MST from apoptotic HPB-ALL cells (27) was also analyzed and indicated as purified 34-kDa MST (A and B). An aliquot of immunoprecipitate was subjected to in vitro kinase assay using histone H2B as substrate (C). Cell lysates were analyzed for DNA fragmentation as a marker of apoptosis (D). E, bacterially expressed His-MST1 (1 µg) and His-MST2 (1 µg) were incubated with (+) or without (-) recombinant active caspase-3 (50 ng) in the presence (+) or absence (-) of 25 µM DEVD-CHO at 30 °C for 30 min. The samples were resolved on SDS-PAGE gel and analyzed by immunoblotting with G2B.

Next, we examined whether the cleavage of MST induces its activation by immune complex kinase assay using histone H2B as substrate. As depicted in Fig. 2, A-D, the phosphorylation of H2B was substantially increased by Fas ligation with approximately the same kinetics as processing of MST and DNA ladder formation. Preincubation with Z-VAD-fmk effectively prevented MST activation for up to 3 h after Fas ligation. Bacterially expressed His-tagged MST1 and MST2 were purified and incubated with active caspase-3 in vitro. His-tagged MST1 and MST2 were completely cleaved to the 34-kDa fragment, and the cleavage was blocked by Z-VAD-fmk (Fig. 2E). These results suggest that both human MST1 and MST2 are physiological substrates of caspase-3 and are proteolytically activated by caspase in Fas-mediated apoptosis.

Evolutionary Conservation of the Cleavage Site in MST-- To address the functional importance of cleavage sequences in human MST1 and MST2 (hMST1 and hMST2), we cloned murine and C. elegans homologues (mMST and cMST, respectively) and compared the polypeptide sequences of hMST1, hMST2, mMST1, mMST2, rat MST2 (rMST2, GenBankTM accession number AJ001529), and cMST (Fig. 3). Murine MST1 and MST2, which show 75% identity to each other, had 97 and 96% homology to human MST1 and MST2, respectively (Fig. 3A). Previously reported cDNA (GenBankTM accession number U28726) that encodes a murine MST2-like polypeptide deleted the C-terminal region, which is caused by single nucleotide deletion. However, we could not obtain MST2 cDNA with nucleotide deletion or alternative splicing from a murine lymphoma WR19L12a cDNA library (28). We obtained only one MST homologue in C. elegans, which showed similar homology (~50%) to mammalian MST1 and MST2. The kinase domain was most conserved, with 95-100% homology between mammalian homologues. Even the kinase domain of cMST showed 75% homology to mammalian MST1 or MST2. The C-terminal 60 amino acids required for dimerization were also highly conserved in all homologues (23) (Fig. 3B). The putative caspase-cleavable sites (Fig. 3B, indicated by arrow) were conserved in all MST homologues, and these homologues were actually cleaved when apoptosis was induced.2 Thus, the functional cleavage sequence for caspase is evolutionarily conserved in MST homologues.


View larger version (79K):
[in this window]
[in a new window]
 
Fig. 3.   Evolutionary conservation of caspase cleavage site in MST homologues. A, overall amino acid sequence homology in MST homologues. B, alignment of C-terminal regions. The conserved caspase recognition site is indicated by an arrow. Arrowhead indicates the novel cleavage sequence in human MST1 identified by peptide sequencing. h, human; m, mouse; r, rat; c, C. elegans.

Two Activation Mechanisms of MST1 following Treatment with Staurosporine-- Previously, Taylor et al. (16) identified a protein kinase responsive to stress (KRS), which was activated by treatment with staurosporine but not by Fas ligation. Subsequent biochemical purification revealed it as MST (16). However, since our result showed that Fas ligation activated MST (27) (Fig. 2), we compared the MST activation by staurosporine treatment and that by Fas ligation in Jurkat cells that undergo apoptosis following these stimulations. Both staurosporine treatment and Fas ligation effectively induced the cleavage of MST1 to 34 kDa (Fig. 4). Unexpectedly, MST1D326N in which the site of cleavage (Asp326) by caspase-3 is mutated to Asn (27) was also processed to a slower migrating fragment of 40 kDa. In addition, the mobility of the 34-kDa fragment was slightly but significantly different in staurosporine- and Fas-induced apoptosis. The reason for the different mobility might be that staurosporine treatment caused a change of phosphorylation state in MST1, which was not caused by Fas stimulation. We investigated the kinase activity of each MST1 fragment by in-gel phosphorylation assay using histone as substrate. Phosphorylation at 55 kDa corresponding to full-length MST1 was greatly increased at 0.5 h by staurosporine treatment and peaked at 1 h (Fig. 4, lanes 1-4). In contrast, Fas ligation could not induce phosphorylation of full-length MST1 up to 3 h (Fig. 4, lanes 5 and 6). Phosphorylation at 40 kDa was also rapidly induced at 0.5 h by staurosporine, although this fragment was not detected in immunoblot analysis. Fas stimulation did not induce a 40-kDa fragment in immunoblot or kinase activity of 40-kDa in-gel kinase assay. The 34-kDa fragment with histone kinase activity was generated from FLAG-MST1 (Fig. 4, lanes 1-6) but not from FLAG-MST1D326N within 3 h by staurosporine and Fas ligation (Fig. 4, lanes 7-12). These results indicate that staurosporine can activate MST by two mechanisms, caspase-independent early activation and caspase-dependent late activation, whereas Fas ligation activates MST only in a caspase-dependent pathway.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 4.   Different activation mechanism of MST1 in staurosporine-and Fas-induced apoptosis. Jurkat cells (1 × 107) were transfected with FLAG-MST1 (WT) or FLAG-MST1D326N. After 48 h post-transfection, apoptosis was induced with 0.5 µM staurosporine (STR) or 0.1 µg/ml of CH-11. After immunoprecipitation with anti-FLAG mAb, immunoblot analysis with anti-FLAG mAb (top) or in-gel kinase assay using histone as substrate (0.2 mg/ml) (bottom) was performed.

Cleavage of MST1D326N to a 40-kDa fragment indicated that another cleavage site exists in the C-terminal region of Asp326, and this cleavage is also the biochemical event involved in apoptosis. His-tagged MST1K59R,D326N was effectively cleaved to 40 kDa in apoptotic Jurkat cell lysate.2 To determine the site of this cleavage, we purified a C-terminal 15-kDa fragment derived from MST1K59R,D326N and performed N-terminal peptide sequencing. It was revealed that Asp349 was the cleavage site, and the peptide sequence surrounding Asp349 (TMTD349G) was similar to the identified caspase recognition sequence of MST homologue, particularly that of cMST (Fig. 3B). We mutated both Asp326 and Asp349 to Asn (MST1D326N,D349N) and tested whether MST1D326N,D349N is resistant to proteolytic cleavage during Fas-mediated apoptosis. MST1D326N,D349N was cleaved to neither the 40- nor to the 34-kDa fragment (Fig. 5). MST2D322N was not cleaved to a smaller fragment indicating that MST2 is cleaved only at Asp322 during apoptosis. In contrast, wild type MST and MST1D326N were cleaved to the 34- and 40-kDa fragment, respectively (Fig. 5). Therefore, MST1 is cleaved at two different sites resulting in a 34- or 40-kDa fragment, and the 40-kDa fragment is further cleaved to 34 kDa.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 5.   MST1 is cleaved at Asp326 and Asp349 in apoptosis. HeLa cells on 6-well plate were transfected with FLAG-MST1 or FLAG-MST2 constructs. After 48 h of post-transfection, apoptosis was induced with of CH-11 (0.1 µg/ml) and cycloheximide (10 µg/ml). Immunoblot analysis (20 µg) was performed with anti-FLAG mAb. WT, wild type.

Apoptotic Morphological Changes Induced by MST1-- To investigate the possible function of MST in apoptosis, we transfected NIH 3T3 cells with FLAG-tagged MST constructs (Fig. 6A). Expression of the various MST1 constructs was confirmed by immunoblotting with anti-FLAG mAb (Fig. 6B, top). Overexpression did not induce MST1 cleavage. The expression level of MST1Delta 327-487, with a C-terminal truncation corresponding to the active MST1 fragment generated by caspase, was very low. In comparison with MST1, MST1Delta 327-487 showed enhanced histone phosphorylation activity but little autophosphorylation activity (Fig. 6B, bottom). A similar result was obtained when FLAG-tagged MST2 was expressed in NIH 3T3 cells.2


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6.   MST kinase activity and its effect on morphological change in NIH 3T3 cells. A, schematic representation of MST1 constructs used in this study. Arrowheads indicate caspase cleavage sites in human MST1. B, FLAG-MST1 constructs were expressed in NIH 3T3 on a 6-well plate and immunoprecipitated with anti-FLAG mAb. Immunoprecipitates were analyzed by immunoblotting with anti-FLAG mAb (top) or in vitro kinase assay (bottom). Kinase assay was performed using histone H2B as substrate at 30 °C for 20 min. The phosphorylated proteins were resolved on 15% SDS-PAGE gel and then analyzed by autoradiography. Arrowhead indicates autophosphorylation activity of MST1Delta 327-487. C, pJ7Omega -LacZ (0.2 µg) was co-transfected with vector (1 µg) expressing caspase-8, MST1K59R, MST1, MST1K59RDelta 327-487, MST1Delta 327-487, PAK2K299R, or PAK2. Cells transfected with MST1 were cultured with or without Z-VAD-fmk (100 µM). At 48 h post-transfection, cells were fixed and stained for beta -galactosidase expression. At least 100 blue cells/sample were counted, and the number of round blue cells was expressed as a percentage of the total number of blue cells. The means of three independent determinations ± S.D. are shown. WT, wild type.

Cells expressing active MST1 showed marked changes resulting in round morphology (Fig. 6C). The morphological change induced by MST1 was indistinguishable from that induced by overexpression of caspase-8, an initiator caspase. However, the round morphology induced by MST1 was not inhibited by the treatment with Z-VAD-fmk, although that by caspase-8 was inhibited by Z-VAD-fmk.2 We compared the morphological change induced by MST1 with that caused by PAK2 (21). Similar change was observed when PAK2 was transfected into NIH 3T3 cells. Neither kinase-negative PAK2K299R, MST1K59R, nor MST1Delta 1-326 deleting N-terminal kinase domain evoked changes in cell morphology indicating that kinase activity of MST1 or PAK2 is required for this morphological change. MST-induced change of morphology was also observed in HeLa cells (Fig. 7). MST-expressing cells were rounded and shrunken with associated destruction of cytoskeletal structure (Fig. 7A). Hyperactive MST1Delta 327-487 showed more dramatic change of morphology and resulted in the loss of MST1Delta 327-487-expressing cells by detachment from substrate. This result may elucidate why the percentage of the round cells in MST1Delta 327-487-transfected cells was reduced in beta -galactosidase assay (Fig. 6C). The enhanced morphological change induced by MST1Delta 327-487 may be the result from the increased kinase activity because kinase-negative MST1K59RDelta 327-487 or MST1K59R did not induce any morphological changes.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 7.   Overexpression of MST induces cell death with apoptosis-like morphology in HeLa cells. HeLa cells cultured on glass chamber slides were transfected with indicated constructs of GFP-MST1 and cultured for 48 h. A, cells were fixed and then observed by green fluorescence microscopy. Expression of kinase-active MST1 (WT) and MST1Delta 327-487 but not kinase-negative MST1K59R and MST1K59RDelta 327-487 induced a round and shrunken morphological appearance. B, cells transfected with GFP-MST1K59R (top) or GFP-MST1 (middle, bottom) were stained with Hoechst 33342 (0.2 µg/ml) at 16 (middle) or 48 h (top, bottom) post-transfection. After washing with PBS, cells were photographed. Representative cells with round morphological appearance are shown. Green and blue indicates fluorescence of GFP and nuclear staining of Hoechst 33342, respectively. DIC, differential interference contrast.

We investigated MST-induced morphological changes in detail. In MST1-expressing HeLa cells at 16 h post-transfection, the cytoplasm was remarkably reduced compared with untransfected cells or transfected cells with MST1K59R (Fig. 7B, top and middle). The morphological change of chromosome was not observed, although the nuclei were slightly reduced and rounded. MST1 and MST1K59R localized in the cytoplasm. At 48 h post-transfection, the cytoplasmic space was completely lost, and cells were eventually detached from the plate (Fig. 7B, bottom). In addition, condensation and fragmentation of chromosome was obvious by Hoechst staining. MST1 appeared to localize in the nucleic area but not overlapped with chromosome. However, these cells were not positive for terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling staining, and the characteristic DNA ladder in apoptosis was not detected on agarose gel electrophoresis.2 These observations indicate that chromosome was not cleaved to much smaller fragments generated by caspase-activated nuclease, such as CAD. We conclude that part of apoptosis-related morphological changes are induced by overexpression of MST, which mimics the caspase-dependent activation of MST in apoptosis.

Nuclear Translocation of Caspase-cleaved MST-- MST1 and MST1K59R were exclusively localized in the cytoplasm when expressed as FLAG-tagged or GFP fusion forms (Fig. 7 and 8A). MST1Delta 1-326 deleting N-terminal kinase domain was also localized in the cytoplasm, but MST1Delta 327-487 was distributed in both cytoplasm and nucleus. To test whether the cytoplasmic localization of MST1 is controlled by active nuclear export, HeLa cells expressing MST1 or MST1Delta 1-326 were treated with leptomycin, an inhibitor of CRM1/exportin (31, 32). MST1 or MST1Delta 1-326 rapidly lost cytoplasmic localization (Fig. 8A). These results indicate that cytoplasmic localization of MST1 is controlled by a C-terminal regulatory region through active nuclear export by the CRM1/exportin (33-35).


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 8.   Nuclear translocation of caspase-cleavable MST1 in Fas-mediated apoptosis. A, indicated FLAG-MST1 constructs were transfected into HeLa cells and cultured for 16 h. Cells were fixed and immunostained with anti-FLAG mAb. Leptomycin (LMB, 10 ng/ml) was treated to the cells transfected with FLAG-MST1 (WT) and FLAG-MST1Delta 1-326 and incubated for 1 h before fixation. B, apoptosis was induced in HeLa cells stably expressing caspase-cleavable GFP-MST1 (top row), GFP-MST1K59R (middle row), or uncleavable GFP-MST1K59R,D326N,D349N (bottom row) by treatment with CH-11 (0.1 µg/ml) and cycloheximide (10 µg/ml) for 2.5 h. Hoechst 33342 (0.2 µg/ml) was added for 30 min before observation. Cells were washed with PBS and observed by fluorescence microscopy without fixation.

To test whether the localization of MST is changed in Fas-mediated apoptosis, we established stable HeLa cell lines expressing caspase-cleavable and uncleavable MST1. MST1 was fused at the C-terminal end of GFP for rapid detection of morphological change and translocation. Established cell lines expressing wild type MST did not show significant morphological differences with control cell lines, although transiently expressed MST induced morphological change (Fig. 7). In the stable cell lines, cleavable and uncleavable MST1 showed a similar cytoplasmic localization before induction of apoptosis.2 However, in early apoptotic cells that showed blebbing of membrane but retained their nuclear structure, cleavable MST1 and MST1K59R translocated into the nucleus although MST1 and MST1K59R were still detected in the cytoplasm (Fig., 8B, top and middle rows). In contrast, uncleavable MST1K59R,D326N,D349N (Fig. 5) remained in the cytoplasm although the apoptosis was apparently occurring as judged by the apoptotic blebbing of membrane (Fig. 8B, bottom row). In later apoptotic cells with nuclear fragmentation, even MST1K59R,D326N,D349N completely lost cytoplasmic localization and was detected in the fragmented nuclei,2 suggesting the translocation after the breakdown of the nuclear envelope. We conclude that MST1 is cytoplasmic protein and the cleaved MST1 translocates into the nucleus before the nuclear fragmentation is initiated.

MST Sensitizes Fas- and TNFalpha -mediated Apoptosis-- To address further the function of MST in apoptosis, we investigated the sensitivity of HeLa cell lines stably expressing MST1 in Fas- and TNFalpha -mediated apoptosis. The expression of GFP-MST1 and GFP-MST1K59R was confirmed by immunoblotting with G2B or with anti-PARP antibody as a control for loading and transfer (Fig. 9A). All sub-cell lines expressing GFP-MST1 were more sensitive to Fas- or TNFalpha -mediated apoptosis than parental HeLa cells or GFP-MST1K59R-expressing cells (Fig. 9B). GFP-MST1K59R did not accelerate or inhibit Fas- or TNFalpha -mediated apoptosis.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 9.   Stable expression of MST1 enhances Fas and TNFalpha -induced apoptosis. A, HeLa cell lines (2 × 106) stably expressing GFP-MST1 (HL-WT1-4) or GFP-MST1K59R (HL-KR1-4) were analyzed for GFP-MST1 expression by immunoblot with G2B. Expression of poly(ADP-ribose) polymerase (PARP) was also measured with anti-poly(ADP-ribose) polymerase antibody as a control for loading and transfer. HL-Neo is a control neomycin-resistant cell line. B, apoptosis was induced by incubation with CH-11 (0.1 µg/ml) or TNFalpha (50 ng/ml) together with cycloheximide (10 µg/ml) for 4 h. The number of cells with apoptotic bodies and membrane blebbing (200-300 cells) was expressed as a percentage of the total number of cells. The means of three independent determinations ± S.D. are shown. C, cells (2 × 106) were treated with CH-11 (0.1 µg/ml) together with cycloheximide (10 µg/ml) for 4 h, and then cell lysate was prepared. Caspase-3-like activity was measured using 50 µM of DEVD-7-amido-4-trifluoromethylcoumarin as substrate. D, two MST1-expressing cell lines (HL-WT1 and HL-WT2) and control HL-Neo cell lines were treated with CH-11 (0.1 µg/ml) and cycloheximide (10 µg/ml) for the indicated times. Cell lysate (50 µg) was analyzed by immunoblot with anti-caspase-3 (top) or with G2B (bottom). Full-length and cleavage products are indicated by arrows and arrowheads, respectively. Other stable cell lines showed essentially similar results.

Interestingly, GFP-MST1 greatly facilitated the activation of caspase-3-like protease in Fas-mediated apoptosis (Fig. 9C) suggesting that MST1 can accelerate caspase-3 activation. To test this possibility, we investigated the cleavage kinetics of caspase-3 in detail. As shown in Fig. 9D, the p17 subunit of caspase-3 was detected at 1.5-2 h in MST1-expressing cell lines (HL-WT1 and HL-WT2) but p17 was detected after 3 h in control cells. Furthermore, the cleavage kinetics of GFP-MST1 was correlated with that of caspase-3 supporting the accelerated activation of caspase-3, because MST1 was shown to be cleaved by activated caspase-3 (Fig. 2). GFP-MST1 did not accelerate the onset of other apoptosis induced by pharmaceutical drugs such as ceramide, staurosporine, and etoposide.2 We conclude that stably expressed MST1 sensitizes death receptor-mediated apoptosis through the accelerated onset of caspase-3 activation.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cleavage and Activation of MST in Apoptosis-- We previously reported that during Fas-mediated apoptosis MST1 and MST2 are proteolytically activated by specific cleavage. However, it remained unclear how MST1 and MST2 are involved in apoptosis. In this study, we clearly show that MST1 and MST2 are physiologically activated by caspase-3-like protease and involved in apoptosis. Caspase cleavage sequences of MST1 (Asp-Glu-Met-Asp326-Ser) and MST2 (Asp-Glu-Leu-Asp322-Ser) are more conserved and optimal than those of other protein kinases known to be activated proteolytically by caspase-3-like proteases including caspase-6 and caspase-7 (27, 36). This probably explains why only MST was purified as a major protein kinase that was activated in Fas-mediated apoptosis (27). Caspase cleavage sequences in MST1 and MST2 are conserved not only in their mammalian but in the nematode homologue, strongly suggesting their biological significance including a role in apoptotic cell death signaling. The cleavage of MST may be a common molecular event in apoptosis since various apoptotic signals induce caspase-dependent MST cleavage, including signals from Fas and TNFalpha receptor, and chemical apoptotic inducers such as staurosporine, etoposide, and ceramide. Recently bisphosphonates, pharmacological drugs for osteoporosis, and anti-tumor drugs such as cytotrienin A have been reported to induce caspase-dependent cleavage of MST in osteoclast and leukemia cells (37, 38).

The cleavage of MST is closely coupled with its activation. Although MST has basal kinase activity in non-apoptotic cells, caspase-dependent MST cleavage induces significant and strong activation of the catalytic fragment. Furthermore, truncated MST, MST1Delta 327-487, has powerful kinase activity supporting the activation by caspase-mediated cleavage. In human MST1, another cleavage site (TMTDG349) was found in this report, which generates a catalytic fragment of 40 kDa. The 40-kDa fragment is detected early in the in-gel kinase assay, whereas the 34-kDa catalytic fragment is detected only at a late time point by staurosporine treatment or Fas stimulation (Fig. 4). Thus, cleavage at Asp349 precedes that at Asp326 and suggests rapid turnover of the 40-kDa fragment to the 34-kDa form. Based on the cleavage kinetics, we conclude that human MST1 is sequentially cleaved at Asp326 and Asp349 in staurosporine-induced apoptosis. However, it is not likely that the cleavage at Asp349 is a prerequisite for MST1 activation because Asp349 is not conserved in murine MST1. In addition, MST1D349N is processed to the 34-kDa fragment with strong kinase activity. Nevertheless, a specific function of the 40-kDa fragment, particularly in early apoptotic events, cannot be ruled out because it shows distinct catalytic activity from the 34-kDa fragment.

Apoptotic Cleavage of MST Induces Nuclear Translocation-- We show that MST is localized exclusively in the cytoplasm. Deletion analysis shows that the C-terminal region of MST is sufficient for cytoplasmic localization that is lost on treatment with leptomycin. Cytoplasmic localization of MST may be regulated by nuclear export signal although the possibility remains that other nuclear export signal-containing proteins or cytoplasmic anchor protein regulates MST localization. MST cleavage by caspase results in the subcellular relocalization of catalytic fragment. In Fas-mediated apoptosis, cleaved MST1 translocates into the nucleus before nuclear fragmentation is initiated. This result suggests additional nuclear functions of cleaved MST1 in apoptosis. Histone H2B is selectively phosphorylated in mammalian apoptotic cells and is associated with chromatin condensation in apoptosis (39). It is of interest to test whether cleaved MST phosphorylates H2B in apoptosis because H2B is an excellent substrate in vitro (Fig. 2 and 6). Caspase-dependent cleavage might affect other biochemical functions of MST. MST1 and MST2 were reported to form homo- or heterodimers through the C-terminal region (23), and cleavage of MST naturally leads to the dissociation of N-terminal catalytic fragments. Therefore, cleavage of MST during apoptosis results in at least three coupled events, activation, monomerization, and translocation of catalytic fragment into the nucleus. These representative regulatory mechanisms, observed in many signaling molecules, may be involved in the apoptotic function of MST.

MST Is Involved in Apoptotic Events-- Overexpression of MST or truncated MST induces morphological changes in cells. These changes are at least partly related to the characteristic morphology of apoptotic cells such as cell rounding, detachment from substratum, and the fragmentation and condensation of nucleus. However, we could not detect other apoptotic characteristics such as externalization of phosphatidylserine, DNA laddering, or formation of apoptotic bodies. These morphological changes induced by MST are similar to those induced by PAK2 (21, 22). Overexpression of each kinase-negative, caspase-resistant form of MST1 and MST2 does not inhibit Fas-mediated apoptosis.2 This suggests that other SPS1/STE20 family members are also involved in apoptosis. Recently, STE20-related kinase, SLK, was reported to be cleaved by caspase-3 and to induce cytoskeletal rearrangement (40-42). Caspase-dependent cleavage and effects on apoptotic morphology of MST, PAK2, and SLK suggest that SPS1/STE20 family kinases are closely involved in apoptosis, probably targeting similar molecules.

Previously it was suggested that overexpression of MST1 activates caspase through the JNK/SAPK kinase pathway (43). However, others (37) could not detect the SAPK/JNK activation. We detected neither the JNK activation nor the caspase activation by overexpression of MST, and PARP, caspase substrate, was not cleaved in our system.2 In addition, the MST1-induced morphological change of the cell was unaffected by preincubation with caspase inhibitor, Z-VAD-fmk (Fig. 6, C and D). Caspase-resistant MST1D326N,D349N still induced similar morphological changes in the presence of caspase inhibitor. Thus, we conclude that morphological changes induced by transient overexpression of MST do not require the activation of caspase, and SAPK/JNK might not be involved in the morphological change.

When stably expressed in the GFP fusion form, MST1 highly sensitizes HeLa cells to Fas- or TNFalpha receptor-mediated apoptosis. Surprisingly, susceptibility to apoptosis was enhanced by accelerated activation of caspase. This result contradicts the finding of transient expression (Fig. 6) that indicates caspase activation is not required for the MST-induced apoptosis-like morphological changes. One possible explanation is that MST has two distinctive functions, direct induction of morphological changes and sensitization to death receptor-mediated apoptosis. The limited apoptotic change induced by transiently expressed MST may reflect MST function downstream of caspase. This explanation is supported by the fact that MST1 is a substrate of caspase, and truncated MST induces morphological changes that are more dramatic. When stably expressed, MST may accelerate caspase activation through the phosphorylation of pro- or anti-apoptotic regulators or caspases. It cannot be ruled out that MST regulates the expression of apoptotic regulators or caspases. Although it is largely unknown how MST is involved in apoptosis, our result clearly shows that it acts as both an upstream activator and a downstream effector of caspase; MST regulates death receptor-induced caspase activation and amplifies caspase-dependent morphological change.

Our result provides some clue to the regulation and function of MST in non-apoptotic cell signaling. Although no physiological activators are known, the rapid activation of MST by staurosporine indicates that there exists a caspase-independent mechanism of activation, which is regulated by upstream kinase(s) or phosphatase(s). Another critical clue to understanding the function of MST may be obtained from the analysis of subcellular localization since some protein kinases are tightly regulated in intracellular spaces (44-46). We propose the regulation of subcellular localization as a possible mechanism regulating cellular function of MST. The identification of physiological substrate will undoubtedly lead to a better understanding of MST function in apoptosis or other cell signaling.

    ACKNOWLEDGEMENT

We thank Masao Murakawa for construction of the FLAG-tagged MST vectors.

    FOOTNOTES

* This work was supported in part by a grant-in-aid for Scientific Research on Priority Areas from the Ministry of Education, Science, and Culture of Japan and a grant-in-aid for Scientific Research from Japan Society for the Promotion of Science.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF271359, AF271360, and AF271361.

To whom correspondence should be addressed: Institute for Virus Research, Kyoto University, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507. Japan. Tel.: 81-75-751-4783; Fax: 81-75-751-4784; E-mail: syonehar@virus.kyoto-u.ac.jp.

Published, JBC Papers in Press, March 7, 2001, DOI 10.1074/jbc.M005109200

2 K.-K. Lee, T. Ohyama, N. Yajima, S. Tsubuki, and S. Yonehara, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: MST, mammalian STE20-like kinase; GFP, green fluorescence protein; PCR, polymerase chain reaction; mAb, monoclonal antibody; PAK, p21-activated kinase; TNF, tumor necrosis factor; Z-, benzyloxycarbonyl-; fmk, fluoromethylketone; PBS, phosphate-buffered saline; JNK, c-Jun N-terminal kinase; SAPK, stress-activated protein kinase; PAGE, polyacrylamide gel electrophoresis; aa, amino acids; X-gal, 5-bromo-4-chloro-3-indolyl beta -D-galactopyranoside.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Vaux, D. L., Haecker, G., and Strasser, A. (1994) Cell 76, 777-779[Medline] [Order article via Infotrieve]
2. Steller, H. (1995) Science 267, 1445-1449[Medline] [Order article via Infotrieve]
3. Thompson, C. B. (1995) Science 267, 1456-1462[Medline] [Order article via Infotrieve]
4. Nagata, S. (1997) Cell 88, 355-365[Medline] [Order article via Infotrieve]
5. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815[Medline] [Order article via Infotrieve]
6. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827[Medline] [Order article via Infotrieve]
7. Imai, Y., Kimura, T., Murakami, A., Yajima, N., Sakamaki, K., and Yonehara, S. (1999) Nature 398, 777-785[CrossRef][Medline] [Order article via Infotrieve]
8. Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. (1995) EMBO J. 14, 5579-5588[Abstract]
9. Nicholson, D. W., and Thornberry, N. A. (1997) Trends Biochem. Sci. 22, 299-306[CrossRef][Medline] [Order article via Infotrieve]
10. Medema, J. P., Scaffidi, C., Kischkel, F. C., Shevchenko, A., Mann, M., Krammer, P. H., and Peter, M. E. (1997) EMBO J. 16, 2794-2804[Abstract/Free Full Text]
11. Thornberry, N. A., and Lazebnik, Y. (1998) Science 281, 1312-1316[Abstract/Free Full Text]
12. Wolf, B. B., and Green, D. R. (1999) J. Biol. Chem. 274, 20049-20052[Free Full Text]
13. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. (1998) Nature 391, 43-50[CrossRef][Medline] [Order article via Infotrieve]
14. Creasy, C. L., and Chernoff, J. (1995) Gene (Amst.) 167, 303-306[CrossRef][Medline] [Order article via Infotrieve]
15. Creasy, C. L., and Chernoff, J. (1995) J. Biol. Chem. 270, 21695-21700[Abstract/Free Full Text]
16. Taylor, L. K., Wang, H. C., and Erikson, R. L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10099-10104[Abstract/Free Full Text]
17. Sells, M. A., and Chernoff, J. (1997) Trends Cell Biol. 7, 162-167[CrossRef]
18. Kyriakis, J. M. (1999) J. Biol. Chem. 274, 5259-5662[Free Full Text]
19. Burbelo, P. D., Drechsel, D., and Hall, A. (1995) J. Biol. Chem. 270, 29071-29074[Abstract/Free Full Text]
20. Tapon, N., Nagata, K., Lamarche, N., and Hall, A. (1998) EMBO J. 17, 1395-1404[Abstract/Free Full Text]
21. Rudel, T., and Bokoch, G. M. (1997) Science 276, 1571-1574[Abstract/Free Full Text]
22. Lee, N., MacDonald, H., Reinhard, C., Halenbeck, R., Roulston, A., Shi, T., and Williams, L. T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13642-13647[Abstract/Free Full Text]
23. Creasy, C. L., Ambrose, D. M., and Chernoff, J. (1996) J. Biol. Chem. 271, 21049-21053[Abstract/Free Full Text]
24. Pombo, C. M., Kehrl, J. H., Sanchez, I., Katz, P., Avruch, J., Zon, L. I., Woodgett, J. R., Force, T., and Kyriakis, J. M. (1995) Nature 377, 750-754[CrossRef][Medline] [Order article via Infotrieve]
25. Pombo, C. M., Bonventre, J. V., Molnar, A., Kyriakis, J., and Force, T. (1996) EMBO J. 15, 4537-4546[Abstract]
26. Pombo, C. M., Tsujita, T., Kyriakis, J. M., Bonventre, J. V., and Force, T. (1997) J. Biol. Chem. 272, 29372-29379[Abstract/Free Full Text]
27. Lee, K. K., Murakawa, M., Nishida, E., Tsubuki, S., Kawashima, S., Sakamaki, K., and Yonehara, S. (1998) Oncogene 16, 3029-3037[CrossRef][Medline] [Order article via Infotrieve]
28. Lee, K. K., Murakawa, M., Takahashi, S., Tsubuki, S., Kawashima, S., Sakamaki, K., and Yonehara, S. (1998) J. Biol. Chem. 273, 19160-19166[Abstract/Free Full Text]
29. Sakamaki, K., Tsukumo, S., and Yonehara, S. (1998) Eur. J. Biochem. 253, 399-405[Abstract]
30. Yonehara, S., Ishii, A., and Yonehara, M. (1989) J. Exp. Med. 169, 1747-1756[Abstract]
31. Kudo, N., Wolff, B., Sekimoto, T., Schreiner, E. P., Yoneda, Y., Yanagida, M., Horinouchi, S., and Yoshida, M. (1998) Exp. Cell Res. 242, 540-547[CrossRef][Medline] [Order article via Infotrieve]
32. Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E. P., Wolff, B., Yoshida, M., and Horinouchi, S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9112-9117[Abstract/Free Full Text]
33. Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., and Nishida, E. (1997) Nature 390, 308-311[CrossRef][Medline] [Order article via Infotrieve]
34. Fornerod, M., Ohno, M., Yoshida, M., and Mattaj, I. W. (1997) Cell 90, 1051-1060[Medline] [Order article via Infotrieve]
35. Ossareh-Nazari, B., Bachelerie, F., and Dargemont, C. (1997) Science 278, 141-144[Abstract/Free Full Text]
36. Cryns, V., and Yuan, J. (1998) Genes Dev. 12, 1551-1570[Free Full Text]
37. Reszka, A. A., Halasy-Nagy, J. M., Masarachia, P. J., and Rodan, G. A. (1999) J. Biol. Chem. 274, 34967-34973[Abstract/Free Full Text]
38. Watabe, M., Kakeya, H., Onose, R., and Osada, H. (2000) J. Biol. Chem. 275, 8766-8771[Abstract/Free Full Text]
39. Ajiro, K. (2000) J. Biol. Chem. 275, 439-443[Abstract/Free Full Text]
40. Sabourin, L. A., and Rudnicki, M. A. (1999) Oncogene 18, 7566-7575[CrossRef][Medline] [Order article via Infotrieve]
41. Sabourin, L. A., Seale, P., Wagner, J., and Rudnicki, M. A. (2000) Mol. Cell. Biol. 20, 684-696[Abstract/Free Full Text]
42. Yamada, E., Tsujikawa, K., Itoh, S., Kameda, Y., Kohama, Y., and Yamamoto, H. (2000) Biochim. Biophys. Acta 1495, 250-262[CrossRef][Medline] [Order article via Infotrieve]
43. Graves, J. D., Gotoh, Y., Draves, K. E., Ambrose, D., Han, D. K., Wright, M., Chernoff, J., Clark, E. A., and Krebs, E. G. (1998) EMBO J. 17, 2224-2234[Abstract/Free Full Text]
44. Engel, K., Kotlyarov, A., and Gaestel, M. (1998) EMBO J. 17, 3363-3371[Abstract/Free Full Text]
45. Mahanty, S. K., Wang, Y., Farley, F. W., and Elion, E. A. (1999) Cell 98, 501-512[Medline] [Order article via Infotrieve]
46. Adachi, M., Fukuda, M., and Nishida, E. (2000) J. Cell Biol. 148, 849-856[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.